Table 2.
Ueno (2016) [11] | |
---|---|
N | 34 |
Objective response rate | 58.8% |
Disease control rate | 94.1% |
Median PFS | 6.5 months |
Median OS | 13.5 months |
Common toxicities (Grade 3/4) | |
Neutropenia | 70.6% |
Febrile neutropenia | 5.9% |
Thrombocytopenia | 14.7% |
Fatigue | - |
Diarrhea | 5.9% |
Peripheral neuropathy | 11.8% |
PFS, Progression-free survival; OS, overall survival.